Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABP NASDAQ:AIMD NASDAQ:ATNF NASDAQ:BCTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABPAbpro$0.25+0.6%$0.24$0.15▼$13.00$19.65M0.037.44 million shs3.32 million shsAIMDAinos$3.82-4.0%$3.04$2.00▼$5.00$17.80M2.2953,529 shs63,597 shsATNF180 Life Sciences$2.87-3.7%$2.98$0.66▼$17.75$17.33M0.3822.03 million shs7.91 million shsBCTXBriacell Therap$7.77+6.4%$14.76$6.00▼$294.00$5.28M1.07113,951 shs49,367 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABPAbpro-0.53%-0.12%-24.64%+12.62%+24,369,900.00%AIMDAinos+4.74%+15.03%+63.11%+17.96%+26.09%ATNF180 Life Sciences-3.87%-43.02%-7.45%+192.16%+53.61%BCTXBriacell Therap-3.95%+11.47%-9.34%-78.65%-93.88%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationABPAbproN/AN/AN/AN/AN/AN/AN/AN/AAIMDAinos1.0595 of 5 stars0.03.00.00.04.31.70.0ATNF180 Life Sciences0.6686 of 5 stars0.02.00.00.03.81.70.0BCTXBriacell Therap2.8746 of 5 stars3.55.00.00.02.60.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABPAbpro 3.00Buy$4.001,547.45% UpsideAIMDAinos 0.00N/AN/AN/AATNF180 Life Sciences 0.00N/AN/AN/ABCTXBriacell Therap 3.00Buy$320.004,104.99% UpsideCurrent Analyst Ratings BreakdownLatest BCTX, ABP, ATNF, and AIMD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/14/2025ATNF180 Life SciencesWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (E+) ➝ Sell (E+)7/29/2025ATNF180 Life SciencesWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (E+) ➝ Sell (E+)7/12/2025ATNF180 Life SciencesWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (E+) ➝ Sell (E+)6/27/2025ATNF180 Life SciencesWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (E+) ➝ Sell (E+)6/11/2025ATNF180 Life SciencesWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (E+) ➝ Sell (E+)(Data available from 8/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABPAbpro$180K108.14N/AN/A($0.21) per share-1.16AIMDAinos$20K885.40N/AN/A$2.46 per share1.54ATNF180 Life SciencesN/AN/AN/AN/A$2.91 per shareN/ABCTXBriacell TherapN/AN/AN/AN/A($22.02) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABPAbpro-$7.23MN/A0.00∞N/AN/AN/A-241.16%N/AAIMDAinos-$14.86M-$4.99N/A∞N/AN/A-108.25%-56.94%11/4/2025 (Estimated)ATNF180 Life Sciences-$6.17M-$15.07N/A∞N/AN/A-141.25%-80.77%11/12/2025 (Estimated)BCTXBriacell Therap-$4.79M-$83.18N/AN/AN/AN/A-479.97%-182.26%10/27/2025 (Estimated)Latest BCTX, ABP, ATNF, and AIMD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025ABPAbproN/A-$0.04N/A-$0.05N/AN/A8/13/2025Q2 2025AIMDAinosN/A-$0.99N/A-$0.99N/AN/A7/23/2025Q2 2025ATNF180 Life SciencesN/A-$0.30N/A-$0.30N/AN/A6/13/2025Q3 2025BCTXBriacell Therap-$17.60-$16.40+$1.20-$1.64N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABPAbproN/AN/AN/AN/AN/AAIMDAinosN/AN/AN/AN/AN/AATNF180 Life SciencesN/AN/AN/AN/AN/ABCTXBriacell TherapN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABPAbproN/A0.150.15AIMDAinos0.962.882.61ATNF180 Life SciencesN/A0.580.58BCTXBriacell TherapN/A3.413.41Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABPAbpro23.30%AIMDAinosN/AATNF180 Life Sciences4.07%BCTXBriacell Therap15.42%Insider OwnershipCompanyInsider OwnershipABPAbpro20.80%AIMDAinos10.39%ATNF180 Life Sciences38.20%BCTXBriacell Therap5.73%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABPAbpro1580.17 million63.49 millionN/AAIMDAinos404.66 million4.17 millionNot OptionableATNF180 Life Sciences76.04 million3.73 millionNo DataBCTXBriacell Therap8680,000639,000No DataBCTX, ABP, ATNF, and AIMD HeadlinesRecent News About These CompaniesHC Wainwright Forecasts Briacell Therap Q1 EarningsAugust 29 at 2:41 AM | americanbankingnews.comBriaCell’s Bria-OTS mechanism of action study published by JCI InsightAugust 26 at 7:16 PM | msn.comBriaCell's Bria-OTS+™ Mechanism of Action Validated in Highly Rated Peer Reviewed Cancer JournalAugust 26 at 7:30 AM | globenewswire.comBriaCell Awarded $2 Million NCI Grant to Advance Bria-PROS+™ in Prostate CancerAugust 25, 2025 | globenewswire.comBriaCell to effect 1-for-10 share consolidation on August 25August 22, 2025 | msn.comBriaCell Announces Proposed Effective Date of Share ConsolidationAugust 21, 2025 | globenewswire.comBriaCell selected for MSK’s 2025 Therapeutics Accelerator Program for Bria-OTS+August 14, 2025 | msn.comBriaCell Selected for MSK's 2025 Therapeutics Accelerator Program for Bria-OTS+™ for CancerAugust 13, 2025 | globenewswire.comBriaCell Announces Proposed Effective Date of Share ConsolidationAugust 5, 2025 | globenewswire.comBriaCell Adds UCLA Health as Key Site in Pivotal Phase 3 Breast Cancer StudyJuly 31, 2025 | globenewswire.comBriaCell Awarded New Zealand Patent for its Whole Cell TechnologyJuly 30, 2025 | globenewswire.comBriaCell's Subsidiary, BriaPro, Files Patent Application for Immuno-Oncology Platform with Novel Multitargeting AgentsJuly 29, 2025 | globenewswire.comBriaCell Announces Two Clinical Data Poster Presentations at ESMO 2025July 25, 2025 | globenewswire.comBriaCell Therapeutics Announces Pricing of $15 million Public OfferingJuly 15, 2025 | globenewswire.comBriaCell Adds Mayo Clinic to Phase 3 Study in Metastatic Breast CancerJuly 15, 2025 | globenewswire.comBriaCell's Bria-IMT™ Demonstrates Survival Advantage over Trodelvy® and Control Group in Metastatic Breast CancerJuly 11, 2025 | globenewswire.comBriaCell Reports Complete and Sustained Resolution of Brain Metastasis and Sustained Regression of Orbital Metastasis in “Eye-Bulging” Breast Cancer PatientJuly 10, 2025 | globenewswire.comBriaCell Patient Achieves Sustained Complete Resolution of Lung Metastasis in Bria-OTS™ Metastatic Breast Cancer StudyJuly 9, 2025 | globenewswire.comBriaCell Phase 2 Survival Achievement: 52% of Patients Surpass One-Year Milestone in Metastatic Breast CancerJuly 8, 2025 | globenewswire.comBriaCell Highlights Additional Phase 3 Clinical Sites Including Los Angeles Cancer Network and Smilow Cancer Hospital at Yale New HavenJuly 2, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBCTX, ABP, ATNF, and AIMD Company DescriptionsAbpro NASDAQ:ABP$0.25 +0.00 (+0.57%) As of 03:59 PM EasternAbpro Holdings Inc. is a biotechnology company. The company's mission is to improve the lives of mankind facing severe and life-threatening diseases with next-generation antibody therapies. Abpro Holdings Inc., formerly known as Atlantic Coastal Acquisition Corp. II, is based in WOBURN, Mass.Ainos NASDAQ:AIMD$3.82 -0.16 (-4.02%) As of 04:00 PM EasternAinos, Inc., a healthcare company, engages in developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos' cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a's broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. It also provides women's health, pneumonia, Ainos Pen, AI Nose, and other products. Ainos, Inc. was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. The company was incorporated in 1984 and is based in San Diego, California.180 Life Sciences NASDAQ:ATNF$2.87 -0.11 (-3.69%) As of 08/28/2025180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed Phase IIb clinical trials that focuses on fibrosis and anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. 180 Life Sciences Corp. is headquartered in Palo Alto, California.Briacell Therap NASDAQ:BCTX$7.77 +0.47 (+6.44%) Closing price 04:00 PM EasternExtended Trading$7.83 +0.06 (+0.72%) As of 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers. BriaCell Therapeutics Corp. is based in West Vancouver, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Ollie’s Bargain Outlet: Buy it While It’s Still a Bargain Best Buy Marketplace: Potential Growth Catalyst or Risky Gimmick? CrowdStrike at a Crossroads: AI Halo vs. Risks Snowflake’s Snowballing Business and Robust Stock Price Outlook NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor NVIDIA Stock Could Pull Back in September, But Don’t Bet on It 3 Reasons Gartner Could Be the Best Buy of Q3 NIO Just Got Its Second Upgrade of the Month, and It’s Big Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access